Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor α selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl) methoxy) benzyl …

…, KM O'Malley, L Zhang, RA Srivastava… - Journal of medicinal …, 2010 - ACS Publications
An 1,3-oxybenzylglycine based compound 2 (BMS-687453) was discovered to be a potent
and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC 50 of …

Novel peroxisome proliferator-activated receptor α agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase …

…, M Blanar, PT Cheng, J Tino, RA Srivastava - … of Pharmacology and …, 2008 - ASPET
The first generation peroxisome proliferator-activated receptor (PPAR) α agonist gemfibrozil
reduces the risk of major cardiovascular events; therefore, more potent PPARα agonists for …

Discovery and preclinical evaluation of BMS-711939, an oxybenzylglycine based PPARα selective agonist

…, KM O'Malley, L Zhang, RA Srivastava… - ACS Medicinal …, 2016 - ACS Publications
BMS-711939 (3) is a potent and selective peroxisome proliferator-activated receptor (PPAR)
α agonist, with an EC 50 of 4 nM for human PPARα and >1000-fold selectivity vs human …

Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 …

NS Srivastava, RAK Srivastava - Phytomedicine, 2019 - Elsevier
… Nishtha Srivastava is a student of veterinary science at Manor … Srivastava conducted
experiments and participated in the interpretation and writing of the manuscript. Rai Ajit Srivastava

[HTML][HTML] AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases …

RAK Srivastava, SL Pinkosky, S Filippov… - Journal of lipid …, 2012 - ASBMB
The adenosine monophosphate-activated protein kinase (AMPK) is a metabolic sensor of
energy metabolism at the cellular as well as whole-body level. It is activated by low energy …

A Novel New Chemical Entity, Gemcabene, Shows Significant Lipid Regulation in PPAR-α Knock-out Mice, Supporting a Mechanism Independent of PPAR-α

CL Bisgaier, RA Srivastava - Circulation, 2015 - Am Heart Assoc
Background: In vitro and cell-based assays with a lipid lowering agent, gemcabene (Gem),
ruled out a direct activation of PPAR-α, although some PPAR-α target genes were modulated …

[HTML][HTML] Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor α-mediated …

RAK Srivastava, N Srivastava, M Averna, RC Lin… - Journal of Biological …, 1997 - ASBMB
The antiatherogenic property of estrogens is mediated via at least two mechanisms: first by
affecting plasma lipoprotein profiles, and second by affecting the components of the vessel …

[HTML][HTML] AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and …

SL Pinkosky, S Filippov, RAK Srivastava… - Journal of lipid …, 2013 - ASBMB
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational
drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk …

Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease

RAK Srivastava - Molecular and cellular biochemistry, 2018 - Springer
Coronary artery disease, the leading cause of death in the developed and developing
countries, is prevalent in diabetes mellitus with 68% cardiovascular disease (CVD)-related …

Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

RAK Srivastava, R Jahagirdar, S Azhar… - Molecular and cellular …, 2006 - Springer
Fenofibrate, a selective 1 PPAR-α activator, is prescribed to treat human dyslipidemia. The
aim of this study was to delineate the mechanism of fenofibrate-mediated reductions in …